170855 ⎘
Detection or diagnosis of diseases; Psychoses; Psychiatry Schizophrenia
GENOMIC ALTERATIONS ASSOCIATED WITH SCHIZOPHRENIA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME
#2BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA
#3METHODS AND SYSTEMS FOR IDENTIFYING OR TREATING CENTRAL NERVOUS SYSTEMS DISEASE
#4ANTI-HERV-W ENVELOPE PROTEIN ANTIBODY FOR USE IN THE TREATMENT OF PSYCHOTIC DISEASES
#5METHODS FOR OPTIMIZING TREATMENT OF MENTAL DISORDERS WITH CANNABIDIOL AND PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL
#6METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY
#7METHODS AND COMPOSITIONS FOR DETECTING COGNITIVE DISORDER
#8BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA
#9BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASES CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME
#10GENOMIC ALTERATIONS ASSOCIATED WITH SCHIZOPHRENIA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME
#11SCREENING METHOD
#12DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS
#13Method for predicting a subjects response to SLC modulator therapy
#14ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF
#15METHODS AND COMPOSITIONS FOR DIAGNOSING, TREATING, AND MONITORING TREATMENT OF SHANK3 DEFICIENCY ASSOCIATED DISORDERS
#16TREATING SCHIZOPHRENIA BASED ON A PANEL OF BIOMARKERS
#17DIAGNOSTIC METHODS FOR NEURAL DISORDERS
#18Mouse with cholinergic neuron-specific inactivated ANO1 gene
#19Biomarkers for bipolar disorder and schizophrenia
#20Screening method
#21DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS
#22Diagnostics Platform for Mitochondrial Dysfunctions/Diseases
#23REDOX PROBING FOR CHEMICAL INFORMATION
#24Antibodies to aripiprazole haptens and use thereof
#25Antibodies to olanzapine and use thereof
#26POLYMORPHISMS FOR PREDICTING TREATMENT RESPONSE TO ANTIPSYCHOTIC DRUGS AND IDENFYING NEW DRUG TARGETS
#27Antibodies to aripiprazole and use thereof
#28SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
#29Screening method
#30METHODS AND COMPOSITIONS FOR DETECTING AND TREATING SCHIZOPHRENIA
#31Diagnostic methods for neural disorders
#32Peptide combinations for use in the diagnosis of schizophrenia
#33Method for treating schizophrenia
#34METHODS AND COMPOSITIONS FOR DIAGNOSING, TREATING, AND MONITORING TREATMENT OF SHANK3 DEFICIENCY ASSOCIATED DISORDERS
#35Method for predicting a subject's response to valproic acid therapy
#36Antibodies to aripiprazole haptens and use thereof
#37Methods of identifying schizophrenia patients at risk for relapse
#38Alpha-Synuclein Antibodies (7A11)
#39BIOMARKER FOR PSYCHIATRIC AND NEUROLOGICAL DISORDERS
#40Biomarker for mental disease
#41Antibodies to risperidone haptens and use thereof
#42Antibodies to olanzapine haptens and use thereof
#43Antibodies to risperidone and use thereof
#44METHODS OF MONITORING FOR ADHERENCE TO ARIPIPRAZOLE THERAPY
#45EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM
#46Antibodies to olanzapine haptens and use thereof
#47Modulation of the VPS10p-Domain Receptor Family for the Treatment of Mental and Behavioural Disorders
#48Quantifying biomarkers for diagnosing and treating schizophrenia, bipolar disorder or major depression
#49Antibodies to aripiprazole haptens and use thereof
#50Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry
#51METHODS OF MONITORING ADHERENCE TO LURASIDONE THERAPY
#52Diagnostic methods for neural disorders
#53SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
#54System and method for diagnosis and treatment of neuropsychiatric disorders
#55Use of known compounds as D-amino acid oxidase inhibitors
#56Antibodies to olanzapine and use thereof
#57Antibodies to aripiprazole and use thereof
#58Biomarkers associated with schizophrenia
#59MENTAL ILLNESS MODEL AND MENTAL ILLNESS RISK ASSESSMENT TEST FOR SCHIZOPHRENIC PSYCHOSIS
#60DIAGNOSTIC METHODS FOR NEURAL DISORDERS
#61GENOMIC ALTERATIONS ASSOCIATED WITH SCHIZOPHRENIA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME
#62Method for detecting indicators for determining diseases
#63Biomarker for psychiatric and neurological disorders
#64Schizophrenia-associated genetic loci identified in genome wide association studies and methods of use thereof
#65Device including biosensor and holder
#66Diagnostic methods for neural disorders
#67SCHIZOPHRENIA MARKER SET AND ITS UTILIZATION
#68INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2
#69COMPOSITIONS AND METHODS FOR TREATING HYPERPROLINEMIA-ASSOCIATED MENTAL DISORDERS
#70COVALENTLY BOUND METABOLITES AS BIOMARKERS
#71System and Method for Detecting and Diagnosing Schizophrenia and Depression
#72GAMMA-AMINOBUTYRIC ACID A RECEPTOR SUBUNIT BIOMARKERS
#73BIOMARKERS
#74Methods of monitoring for adherence to aripiprazole therapy
#75Screening method
#76Treating schizophrenia based on a panel of biomarkers
#77Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
#78Antibodies to olanzapine and use thereof
#79Antibodies to risperidone and use thereof
#80Antibodies to risperidone haptens and use thereof
#81Antibodies to aripiprazole and use thereof
#82Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
#83Method for diagnosing and monitoring schizophrenia and tauopathies
#84BIOMARKERS
#85PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME
#86BIOMARKERS
#87BIOMARKERS
#88Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
#89CLOZAPINE IMMUNOASSAY
#90Method for binding a recombinant polypeptide to a carrier
#91BIOMARKERS FOR SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS
#92SCHIZOPHRENIA TREATMENT RESPONSE BIOMARKERS
#93DIAGNOSIS AND TREATMENT OF THE PRODROMAL SCHIZOPHRENIC STATE
#94Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
#95COMPOSITIONS AND METHODS FOR EVALUATING COGNITIVE DEFECTS
#96SCHIZOPHRENIA METHODS AND COMPOSITIONS
#97Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platform
#98System and Method for Diagnosis and Treatment of Neuropsychiatric Disorders
#99Polypeptides that inhibit dopamine D2 receptor-DISC1 interaction and methods of use thereof
#100Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
#101BIOMARKERS
#102IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING ELECTRODES WITH MICROVOLTAMMETRY
#103PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS
#104Genetic Alterations Associated with Schizophrenia and Methods of Use Thereof for the Diagnosis and Treatment of the Same
#105COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MENTAL DISORDERS
#106IMAGING NEUROLEPTIC COMPOUNDS
#107METHODS AND BIOMARKERS FOR DIAGNOSING AND MONITORING PSYCHOTIC DISORDERS
#108IDENTIFICATION OF A MOLECULAR SIGNATURE FOR ANTIPSYCHOTICS AND SERMS
#109Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
#110Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
#111METHOD FOR DIAGNOSING AND TREATING CHRONIC PSYCHIATRIC ILLNESSES AND MARKERS AND TARGETS FOR SUCH METHODS
#112Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1
#113COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING NEUROPSYCHIATRIC DISORDERS
#114Therapy for hyperexcitability disorders
#115Biomarkers for psychosis
#116MEASUREMENT OF NEURAL ACTIVITY
#117Biological Load Indicator and Method of Measuring Biological Load
#118Altered Mitochondrial Activity in Diseases Resulting From Oxidative Stress
#119Methods and biomarkers for diagnosing and monitoring psychotic disorders
#120GENES AND PATHWAYS INVOLVED IN BIPOLAR DISORDER
#121Method of treating depression
#122Promoter variants of the alpha-7 nicotinic acetylcholine receptor
#123Lipidomics approaches for central nervous system disorders
#124METHOD FOR IDENTIFYING CRMP MODULATORS
#125Methods of treating psychosis and schizophrenia based on polymorphisms in the CNTF gene
#126Methods and compositions for the diagnosis and treatment of schizophrenia
#127Method for identifying antipsychotic drug candidates
#128VDCC Gamma-8 Ion Channel
#129Methods and kits for diagnosis of schizophrenia
#130Methods and compositions for the diagnosis and treatment of schizophrenia
#131Catecholamine regulated protein
#132Antibody for diagnosing neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders
#133Neuregulin-1 transgenic mouse and methods of use
#134Neurgulin 1 (NRG1) - ErbB4 signaling as a target for the treatment of schizophrenia
#135System and method for diagnosis of neuropsychiatric disorders
#136Genes Commonly Regulated by Different Classes of Antidepressants
#137Methods for diagnosing bipolar disorder
#138Methods for diagnosing major depression or schizophrenia
#139Methods for Diagnosing Schizophrenia
#140Proteins related to schizophrenia and uses thereof
#141Methods of identifying agents for treatment of schizophrenia and related disorders
#142METHODS OF IDENTIFYING AGENTS FOR TREATING NEUROLOGICAL DISORDERS
#143METHODS OF TREATING PSYCHOSIS AND SCHIZPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE
#144Animal model for schizophrenia
#145METHODS AND SYSTEMS FOR FACILITATING THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
#146Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry
#147Use of pp2a phosphatase modulators in the treatment of mental disorders
#148Compositions and methods for diagnosing and treating neuropsychiatric disorders
#149Method of diagnosing integration dysfunction syndrome using blood
#150Proteins related to schizophrenia and uses thereof
#151Method for diagnosing a predisposition of psychosis in a progeny
#152Materials and methods for identifying anti-schizophrenic agents
#153Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
#154Compositions and methods for diagnosing and treating mental disorders
#155Multi-parameter high throughput screening assays (MPHTS)
#156Method of examining and diagnosing integration dysfunction syndrome
#157Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
#158Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene
#159Methods of screening for schizophrenia
#160Autoimmunity to angiotensin at1 receptors in schizophrenia
#161Molecular diagnostic kits for evaluating stress